Clinical Trial: Exploratory Study of Venetoclax, Homoharringtonine, Azacitidine Plus G-CSF for Newly Diagnosed AML (VHAG)

U.S., April 3 -- ClinicalTrials.gov registry received information related to the study (NCT07507825) titled 'Exploratory Study of Venetoclax, Homoharringtonine, Azacitidine Plus G-CSF for Newly Diagnosed AML (VHAG)' on March 22.

Brief Summary: This study is a single-arm, prospective, multi-center exploratory clinical trial. A total of 61 patients with newly diagnosed acute myeloid leukemia (AML) who are not suitable for intensive chemotherapy will be enrolled. The Simon two-stage design will be adopted to control the type I and type II errors, with the minimum acceptable composite remission rate of 65% and a power of 80%.

Prior to treatment, subjects will undergo screening within 28 days, including bone marrow aspiration, genetic testing,...